ArticleEFSA journal. European Food Safety Authority2023
Statement on how to interpret the QPS qualification on 'acquired antimicrobial resistance genes'.
Article in EFSA journal. European Food Safety Authority, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 47 citations in OpenAlex.
- Assessment of the feed additive consisting of l-threonine produced withEFSA journal. European Food Safety Authority · 2026Article
- Safety and efficacy of feed additives consisting of l-lysine monohydrochloride and liquid l-lysine produced withEFSA journal. European Food Safety Authority · 2026Article
- Safety and efficacy of a feed additive consisting of l-threonine produced usingEFSA journal. European Food Safety Authority · 2026Article
- Safety and efficacy of the feed additives consisting of l-isoleucine ≥ 90% and l-isoleucine ≥ 65% produced withEFSA journal. European Food Safety Authority · 2026Article
- Endogenous CRISPR-Based Removal of Tetracycline Resistance in Bifidobacterium animalis subsp. lactis Through a Safe-by-Design Approach.Microbial biotechnology · 2026Article
- Safety and efficacy of a feed additive consisting of l-isoleucine produced withEFSA journal. European Food Safety Authority · 2026Article
- Key Safety Criteria for Novel Microbial Food Ingredients: A Comparative Analysis of International Regulatory Frameworks.Journal of microbiology and biotechnology · 2026Review
- Safety and efficacy of a feed additive consisting of l-leucine produced withEFSA journal. European Food Safety Authority · 2026Article
- Update of the list of qualified presumption of safety (QPS) recommended microbiological agents intentionally added to food or feed as notified to EFSA 24: Suitability of taxonomic units notified to EFSA until March 2026.EFSA journal. European Food Safety Authority · 2026Article
- Safety of lacto-N-triose II as a novel food pursuant to Regulation (EU) 2015/2283.EFSA journal. European Food Safety Authority · 2026Article
- Whole-genome sequencing reveals hidden antimicrobial resistance genes in phenotypically susceptible probiotic candidate lactic acid bacteria.Scientific reports · 2026Article
- Exploring the Probiotic and Antimicrobial Potential of Pediococcus Pentosaceus Isolates from Fish: Genomic and Functional Perspectives.Probiotics and antimicrobial proteins · 2026Article
- Whole-genome sequencing and in vitro characterization of two lactic acid bacteria isolates with potent antimicrobial activity from fermented vegetables.BMC microbiology · 2026Article
- Safety and efficacy of a feed additive consisting of l-valine produced withEFSA journal. European Food Safety Authority · 2026Article
- Water kefir as a paradigm for multi-omics and genome-scale metabolic modelling in fermented food.NPJ biofilms and microbiomes · 2026Review
- Safety and efficacy of a feed additive consisting of l-arginine produced withEFSA journal. European Food Safety Authority · 2026Article
- Safety and efficacy of a feed additive consisting of l-histidine monohydrochloride monohydrate produced withEFSA journal. European Food Safety Authority · 2026Article
- Safety and efficacy of a feed additive consisting of l-lysine sulfate produced usingEFSA journal. European Food Safety Authority · 2026Article
- Safety and efficacy of a feed additive consisting of l-isoleucine produced withEFSA journal. European Food Safety Authority · 2026Article
- Update of the list of QPS-recommended biological agents intentionally added to food or feeds as notified to EFSA.EFSA journal. European Food Safety Authority · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The qualified presumption of safety (QPS) approach was developed to provide a regularly updated generic pre-evaluation of the safety of microorganisms intended for use in the food or feed chains. Safety concerns identified for a taxonomic unit (TU) are, where possible, confirmed at the species/strain or product level and reflected by 'qualifications' which should be assessed at strain and/or product level by EFSA's Scientific Panels. The generic qualification 'the strains should not harbour any acquired antimicrobial resistance (AMR) genes to clinically relevant antimicrobials' applies to all QPS bacterial TUs. The different EFSA risk assessment areas use the same approach to assess the qualification related to AMR genes. In this statement, the terms 'intrinsic' and 'acquired' AMR genes were defined for the purpose of EFSA's risk assessments, and they apply to bacteria used in the food and feed chains. A bioinformatic approach is proposed for demonstrating the 'intrinsic'/'acquired' nature of an AMR gene. All AMR genes that confer resistance towards 'critically important', 'highly important' and 'important' antimicrobials, as defined by the World Health Organisation (WHO), found as hits, need to be considered as hazards (for humans, animals and environment) and need further assessment. Genes identified as responsible for 'intrinsic' resistance could be considered as being of no concern in the frame of the EFSA risk assessment. 'Acquired' AMR genes resulting in a resistant phenotype should be considered as a concern. If the presence of the 'acquired' AMR gene is not leading to phenotypic resistance, further case-by-case assessment is necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.